It is an ugly ailment with an ugly name. But after years of trying, the pharmaceuticals industry is getting to grips with the multibillion-dollar problem of fatty liver disease.
This month Pennsylvania-based biotech Madrigal became the first to win approval for a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The breakthrough is badly needed. This liver disease already affects one in 20 of the world’s adults and its prevalence is rising with obesity.
Madrigal will make the most of its head start. It is now raising $600mn to launch its pioneering drug Rezdiffra in the US. Madrigal’s market value is about $5.1bn. But Bloomberg data for analysts’ 12-month price targets would lift that by more than a third.
您已阅读27%（739字），剩余73%（1961字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。